H&H INTL HLDG(01112) announces annual performance, with a net profit attributable to shareholders of 1.96 billion yuan, turning losses into profits year-on-year. Swisse achieved a milestone of one billion U.S. dollars in revenue in 2025.

H&H International Holdings (01112) announced its annual results for the year ended December 31, 2025. The group achieved a revenue of RMB 14.354 billion, an increase of 10% year-on-year; the attributable profit to owners of the parent company was RMB 196 million, turning losses into profits year-on-year; basic earnings per share were HK$0.31; proposed final dividend of HK$0.16 per share. 2025 was an encouraging year for the group, marking significant progress in all aspects of the group's strategy. All business segments, including adult nutrition and care products, infant and child nutrition and care products, and pet nutrition and care products, regained momentum and achieved steady and broad growth, while continuing to develop in strategic and financial priority areas. Key highlights for the year include: Achieving solid financial performance: Total revenue for the year increased by 10.3% compared to the previous year. The group maintained a stable level of profitability, with an adjusted comparable EBITDA margin of 14.3% and a 22.7% increase in adjusted comparable net profit. Consolidating market leadership in adult nutrition and care products: After a decade of strategic governance, Swisse reached a milestone of one billion US dollars in revenue in 2025. In 2025, Swisse ranked first in the overall vitamin, herbal, and mineral supplement market in mainland China and the Australian market, achieving double-digit growth in mainland China and expansion markets. Reviving growth momentum in infant and child nutrition and care products: The group's infant and child nutrition and care products business in mainland China has regained growth momentum, primarily due to the successful turnaround of the infant formula business after the completion of the new "national standard" transition. The group's market share in the ultra-premium infant formula segment increased from 13.3% in 2024 to a new high of 17.1% in 2025, surpassing market levels. Expanding pet nutrition and care products as a significant growth engine: In 2025, the pet nutrition and care products segment accounted for 15.0% of total revenue, benefiting from an 8.7% year-on-year growth in overall pet nutrition and care products and a 14.3% year-on-year growth in high-growth pet nutrition products. Accelerating deleveraging of the balance sheet: The group's net leverage ratio decreased significantly from 3.99 times in 2024 to 3.45 times in 2025, benefiting from strong operating cash flow and optimized capital structure. During the year, the group reduced total debt by over RMB 600 million while maintaining a robust cash reserve of over RMB 1.7 billion, accelerating the deleveraging process.